Diabetes: treating hypertension


| Abstract | Cite as


INTRODUCTION: Between 2007 and 2010, the age-adjusted prevalence of hypertension in US adults with diabetes was 59%, more than double the prevalence in those without diabetes. Major cardiac events occur in approximately 5% of people with diabetes and untreated hypertension each year, and the risk is higher in those with other risk factors, such as diabetic nephropathy. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of different blood pressure targets in people with diabetes and hypertension? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 10 studies that met our inclusion criteria. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following intervention: more intensive (lower) blood pressure targets versus less intensive (higher) targets in people with diabetes and hypertension.

Cite as

Vijan S. Diabetes: treating hypertension. Clinical Evidence 2014; 06:608.


Substantive changes at this update

More intensive (lower) blood pressure targets versus less intensive (higher) blood pressure targets New evidence added.[15][16][18][19][20] Categorisation changed (likely to be beneficial).

Latest citations

Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. ( 16 March 2015 )

Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. ( 16 March 2015 )